DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET. A live webcast will be available and a replay will remain on the company site for 90 days.
Investors can access the live webcast via the company’s Events page and view the replay through the investor website.
Details
News Market Reaction – DBVT
On Feb 10, the first trading day after this news, DBVT closed 7.11% above the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Summit dates
- February 11-12, 2026
- Dates of Guggenheim Securities Emerging Outlook: Biotech Summit
- Presentation date
- Thursday, February 12
- Scheduled date for CEO fireside chat
- Presentation time
- 2:30pm ET
- Scheduled time for the Guggenheim fireside chat
- Replay window
- 90 days
- Replay availability on DBV Technologies’ website after the event
Historical Context
-
Updated disclosure of total shares and voting rights as of Jan 31, 2026.
-
Reported €166.7M gross proceeds from full exercise of March 2025 warrants.
-
Revised total shares and voting rights as of Dec 31, 2025 after warrant exercises.
-
Half-year liquidity contract report detailing share and cash balances and trades.
-
Initial Dec 31, 2025 share and voting-rights disclosure under AMF regulations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, February 9, 2025
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé’s presentation is scheduled for Thursday, February 12, at 2:30pm ET.
A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/
A replay will be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.